Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 1037-1049 , December 2007

Mixed connective tissue disease: what is behind the curtain?

  • Martin Aringer, MD (Chief)

      Affiliations

    • Corresponding Author InformationCorresponding author. Professor of Medicine, Division of Rheumatology, Department of Medicine III, University Clinical Center Carl Gustav Carus, Fetscherstrasse 74, 01307 Dresden, Germany. Tel.: +49 351 458 4422; Fax: +49 351 458 5801.

References 

  1. Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). American Journal of Medicine. 1972;52:148–159
  2. Sharp GC, Irvin WS, May CM, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. The New England Journal of Medicine. 1976;295:1149–1154
  3. Black C, Isenberg DA. Mixed connective tissue disease – goodbye to all that. British Journal of Rheumatology. 1992;31:695–700
  4. Alarcon-Segovia D. Shared autoimmunity: a concept for which the time has come. Autoimmunity. 2005;38:201–203
  5. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. The Journal of Clinical Investigation. 1998;101:273–281
  6. Targoff IN. Autoantibodies in polymyositis. Rheumatic Disease Clinics of North America. 1992;18:455–482
  7. Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. The Quarterly Journal of Medicine. 1990;77:1019–1038
  8. Hengstman GJ, van Engelen BG, Vree Egberts WT, van Venrooij WJ. Myositis-specific autoantibodies: overview and recent developments. Current Opinion In Rheumatology. 2001;13:476–482
  9. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Annals of the Rheumatic Diseases. 2007;66:754–763
  10. Reimer G, Steen VD, Penning CA, et al. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis & Rheumatism. 1988;31:525–532
  11. Steen VD. Autoantibodies in systemic sclerosis. Seminars in Arthritis and Rheumatism. 2005;35:35–42
  12. Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. The Journal of Clinical Investigation. 1996;98:785–792
  13. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. The New England Journal of Medicine. 2006;354:2667–2676
  14. Servettaz A, Tamby MC, Guilpain P, et al. Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). Clinical Immunology. 2006;120:212–219
  15. Hu PQ, Fertig N, Medsger TA, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis & Rheumatism. 2003;48:1363–1373
  16. Henault J, Robitaille G, Senecal JL, Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis & Rheumatism. 2006;54:963–973
  17. Henault J, Tremblay M, Clement I, et al. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis & Rheumatism. 2004;50:3265–3274
  18. Williams HJ, Alarcon GS, Joks R, et al. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. The Journal of Rheumatology. 1999;26:816–825
  19. Bodolay E, Csiki Z, Szekanecz Z, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clinical and Experimental Rheumatology. 2003;21:313–320
  20. Mosca M, Neri R, Bencivelli W, et al. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum follow up of 5 years. The Journal of Rheumatology. 2002;29:2345–2349
  21. Swaak AJ, van de BH, Smeenk RJ, et al. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford). 2001;40:89–94
  22. Grennan DM, Bunn C, Hughes GR, et al. Frequency and clinical significance of antibodies to ribonucleoprotein in SLE and other connective tissue disease subgroups. Annals of the Rheumatic Diseases. 1977;36:442–447
  23. Habets WJ, de Rooij DJ, Hoet MH, et al. Quantitation of anti-RNP and anti-Sm antibodies in MCTD and SLE patients by immunoblotting. Clinical and Experimental Immunology. 1985;59:457–466
  24. Vlachoyiannopoulos PG, Guialis A, Tzioufas G, Moutsopoulos HM. Predominance of IgM anti-U1RNP antibodies in patients with systemic lupus erythematosus. British Journal of Rheumatology. 1996;35:534–541
  25. Frandsen PB, Kriegbaum NJ, Ullman S, et al. Follow-up of 151 patients with high-titer U1RNP antibodies. Clinical Rheumatology. 1996;15:254–260
  26. Lerner MR, Steitz JA. Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America. 1979;76:5495–5499
  27. Lundberg I, Nyman U, Pettersson I, Hedfors E. Clinical manifestations and anti-(U1)snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients. British Journal of Rheumatology. 1992;31:811–817
  28. Hof D, Cheung K, de Rooij DJ, et al. Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease. Arthritis Research & Therapy. 2005;7:R302–R309
  29. Greidinger EL, Foecking MF, Ranatunga S, Hoffman RW. Apoptotic U1-70 kd is antigenically distinct from the intact form of the U1-70-kd molecule. Arthritis & Rheumatism. 2002;46:1264–1269
  30. Okawa-Takatsuji M, Aotsuka S, Uwatoko S, et al. Endothelial cell-binding activity of anti-U1-ribonucleoprotein antibodies in patients with connective tissue diseases. Clinical and Experimental Immunology. 2001;126:345–354
  31. Okawa-Takatsuji M, Aotsuka S, Uwatoko S, et al. Increase of cytokine production by pulmonary artery endothelial cells induced by supernatants from monocytes stimulated with autoantibodies against U1-ribonucleoprotein. Clinical and Experimental Rheumatology. 1999;17:705–712
  32. Furtado RN, Pucinelli ML, Cristo VV, et al. Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients. Lupus. 2002;11:35–41
  33. Reichlin M, van Venrooij WJ. Autoantibodies to the URNP particles: relationship to clinical diagnosis and nephritis. Clinical and Experimental Immunology. 1991;83:286–290
  34. Greidinger EL, Zang Y, Jaimes K, et al. A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen. Arthritis & Rheumatism. 2006;54:661–669
  35. Burdt MA, Hoffman RW, Deutscher SL, et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis & Rheumatism. 1999;42:899–909
  36. Bodolay E, Szekanecz Z, Devenyi K, et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford). 2005;44:656–661
  37. Leibfarth JH, Persellin RH. Characteristics of patients with serum antibodies to extractable nuclear antigens. Arthritis & Rheumatism. 1976;19:851–856
  38. Cohen ML, Dawkins B, Dawkins RL, Owen ET. Clinical significance of antibodies to ribonucleoprotein. Annals of the Rheumatic Diseases. 1979;38:74–78
  39. Smolen JS, Steiner G. Mixed connective tissue disease: to be or not to be?. Arthritis & Rheumatism. 1998;41:768–777
  40. Farber SJ, Bole GG. Antibodies to components of extractable nuclear antigen. Clinical characteristics of patients. Archives of Internal Medicine. 1976;136:425–431
  41. van den Hoogen FH, Spronk PE, Boerbooms AM, et al. Long-term follow-up of 46 patients with anti-(U1)snRNP antibodies. British Journal of Rheumatology. 1994;33:1117–1120
  42. Prakash UB. Lungs in mixed connective tissue disease. Journal of Thoracic Imaging. 1992;7:55–61
  43. Ramos-Niembro F, Alarcon-Segovia D, Hernandez-Ortiz J. Articular manifestations of mixed connective tissue disease. Arthritis & Rheumatism. 1979;22:43–51
  44. Piirainen HI. Patients with arthritis and anti-U1-RNP antibodies: a 10-year follow-up. British Journal of Rheumatology. 1990;29:345–348
  45. O'Connell DJ, Bennett RM. Mixed connective tissue disease – clinical and radiological aspects of 20 cases. British Journal of Radiology. 1977;50:620–625
  46. Takasaki Y, Yamanaka K, Takasaki C, et al. Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Modern Rheumatology. 2004;14:367–375
  47. Gendi NS, Welsh KI, van Venrooij WJ, et al. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis & Rheumatism. 1995;38:259–266
  48. Berglin E, Padyukov L, Sundin U, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Research & Therapy. 2004;6:R303–R308
  49. Oxenhandler R, Hart M, Corman L, et al. Pathology of skeletal muscle in mixed connective tissue disease. Arthritis & Rheumatism. 1977;20:985–988
  50. Bennett RM, O'Connell DJ. Mixed connective tisssue disease: a clinicopathologic study of 20 cases. Seminars in Arthritis and Rheumatism. 1980;10:25–51
  51. Hall S, Hanrahan P. Muscle involvement in mixed connective tissue disease. Rheumatic Disease of Clinics North America. 2005;31:509–517vii
  52. Barakat S, Briand JP, Abuaf N, et al. Mapping of epitopes on U1 snRNP polypeptide A with synthetic peptides and autoimmune sera. Clinical and Experimental Immunology. 1991;86:71–78
  53. Skriner K, Sommergruber WH, Tremmel V, et al. Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease. The Journal of Clinical Investigation. 1997;100:127–135
  54. Hassan AB, Nikitina-Zake L, Padyukov L, et al. MICA4/HLA-DRB1*04/TNF1 haplotype is associated with mixed connective tissue disease in Swedish patients. Human Immunology. 2003;64:290–296
  55. Hoffman RW, Rettenmaier LJ, Takeda Y, et al. Human autoantibodies against the 70-kd polypeptide of U1 small nuclear RNP are associated with HLA-DR4 among connective tissue disease patients. Arthritis & Rheumatism. 1990;33:666–673
  56. Hameenkorpi R, Ruuska P, Forsberg S, et al. More evidence of distinctive features of mixed connective tissue disease. Scandinavian Journal of Rheumatology. 1993;22:63–68
  57. Dong RP, Kimura A, Hashimoto H, et al. Difference in HLA-linked genetic background between mixed connective tissue disease and systemic lupus erythematosus. Tissue Antigens. 1993;41:20–25
  58. Ruuska P, Hameenkorpi R, Forsberg S, et al. Differences in HLA antigens between patients with mixed connective tissue disease and systemic lupus erythematosus. Annals of the Rheumatic Diseases. 1992;51:52–55
  59. Kaneoka H, Hsu KC, Takeda Y, et al. Molecular genetic analysis of HLA-DR and HLA-DQ genes among anti-U1-70-kd autoantibody positive connective tissue disease patients. Arthritis & Rheumatism. 1992;35:83–94
  60. Black CM, Maddison PJ, Welsh KI, et al. HLA and immunoglobulin allotypes in mixed connective tissue disease. Arthritis & Rheumatism. 1988;31:131–134
  61. Genth E, Zarnowski H, Mierau R, et al. HLA-DR4 and Gm(1,3;5,21) are associated with U1-nRNP antibody positive connective tissue disease. Annals of the Rheumatic Diseases. 1987;46:189–196
  62. Amigues JM, Cantagrel A, Abbal M, Mazieres B. Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. The Journal of Rheumatology. 1996;23:2055–2062
  63. Alarcon-Segovia D, Villareal M. Classification and diagnostic criteria for mixed connective tissue disease. In:  Kasukawa R,  Sharp GC editor. Mixed connective tissue diseases and antinuclear antibodies. Amsterdam: Elsevier; 1987;p. 41–47
  64. Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheumatic Disease Clinics of North America. 2005;31:411–420
  65. Grader-Beck T, Wigley FM. Raynaud's phenomenon in mixed connective tissue disease. Rheumatic Disease of Clinics North America. 2005;31:465–481vi
  66. Pope JE. Other manifestations of mixed connective tissue disease. Rheumatic Disease Clinics of North America. 2005;31:519–533vii
  67. Bull TM, Fagan KA, Badesch DB. Pulmonary vascular manifestations of mixed connective tissue disease. Rheumatic Disease Clinics of North America. 2005;31:451–464vi
  68. Gluck T, Muller-Ladner U, Speicher A, et al. Fatal sinus vein thrombosis in a patient with mixed connective tissue disease and secondary antiphospholipid antibody syndrome. Medizinische Klinik (Munich). 2001;96:361–364
  69. Mendonca LL, Amengual O, Atsumi T, et al. Most anticardiolipin antibodies in mixed connective tissue disease are beta2-glycoprotein independent. The Journal of Rheumatology. 1998;25:189–190
  70. Venables PJ. Mixed connective tissue disease. Lupus. 2006;15:132–137
  71. Kitridou RC, Akmal M, Turkel SB, et al. Renal involvement in mixed connective tissue disease: a longitudinal clinicopathologic study. Seminars in Arthritis and Rheumatism. 1986;16:135–145
  72. Kim P, Grossman JM. Treatment of mixed connective tissue disease. Rheumatic Disease Clinics of North America. 2005;31:549–565viii
  73. Greenberg SA, Amato AA. Inflammatory myopathy associated with mixed connective tissue disease and scleroderma renal crisis. Muscle & Nerve. 2001;24:1562–1566
  74. Sullivan WD, Hurst DJ, Harmon CE, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore). 1984;63:92–107
  75. Hammann C, Genton CY, Delabays A, et al. Myocarditis of mixed connective tissue disease: favourable outcome after intravenous pulsed cyclophosphamide. Clinical Rheumatology. 1999;18:85–87
  76. Bhinder S, Harbour K, Majithia V. Transverse myelitis, a rare neurological manifestation of mixed connective tissue disease – a case report and a review of literature. Clinical Rheumatology. 2007;26:445–447
  77. Ulmer A, Kotter I, Pfaff A, Fierlbeck G. Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease. Journal of American Academy of Dermatology. 2002;46:123–127
  78. Matsuda M, Miki J, Oguchi K, et al. Fasciitis in mixed connective tissue disease successfully treated with high-dose intravenous immunoglobulin. Internal Medicine. 2003;42:910–911
  79. Christopher-Stine L, Wigley F. Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. The Journal of Rheumatology. 2003;30:2725–2727
  80. Cohen LE, Faske I, Fenske NA, Greist MA. Prostaglandin infusion therapy for intermittent digital ischemia in a patient with mixed connective tissue disease. Case report and review of the literature. Journal of American Academy of Dermatology. 1989;20:893–897

PII: S1521-6942(07)00110-6

doi: 10.1016/j.berh.2007.10.002

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 1037-1049 , December 2007

Article Tools

* Image Usage & Resolution